Anita K Wagner

Biographic Data

ID	5534394
NAME	Anita K Wagner
GIVEN NAMES	Anita K
FAMILY NAME	Wagner
SIGNATURE	WAGNER A K
AFFILIATIONS	Harvard University
ORCID	0000-0002-1069-6668
VERIFIED	Yes
TOTAL WORKS	20
TOTAL CITATIONS	10
AUTHOR COUNT	20
EDITOR COUNT	0
FIRST PUBLICATION YEAR	1992
LATEST PUBLICATION YEAR	2025
H-INDEX	2

Preventive Drug Lists Reduce Income-Related Disparities in Medication Adherence Over 2 Years
Dennis Ross-Degnan, Stephanie Argetsinger et al.ARTICLEMedical Care2025References: 23
BACKGROUND: Employers add Preventive Drug Lists (PDLs) to commercial insurance plans to reduce out-of-pocket payments for medicines that treat important chronic illnesses. OBJECTIVE: This study examined the impact of PDLs among patients with pre-existing diabetes. RESEARCH DESIGN: Interrupted time series design with difference-in-difference analysis. SUBJECTS: We identified 5575 patients aged 12-64 with diabetes whose employers adopted PDL covera…
Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
Open AccessYue Zhou, Huseyin Naci et al.ARTICLEBMJ Global Health2023
INTRODUCTION: We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months and high scores on European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). METHODS: We identified applications for cancer drug in WHO EMLs from 2015 to 2021. We extracte…
The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China
Open AccessYu Yang, Yichen Zhang et al.ARTICLEJournal of Global Health2023
Background: High prices of targeted anticancer medicines (TAMs) result in financial toxicity for patients and the health insurance system. How national price negotiation and reimbursement policy affect the accessibility of TAMs for cancer patients remains unknown. Methods: In this population-based cohort study, we used national health insurance claims data in 2017 and identified adult patients with cancer diagnoses for which price-negotiated TAMs…
Ultraexpensive gene therapies, industry interests and the right to health
Open AccessAdriana Mitsue Ivama-Brummell, Anita K Wagner et al.ARTICLEBMJ Global Health2022
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
Open AccessYichen Zhang, Haishaerjiang Wushouer et al.ARTICLEBMJ Global Health2021
INTRODUCTION: New targeted therapies have changed cancer treatment in the past decades. However, high prices of targeted anticancer medications have increased economic burden for both patients and health insurance systems. In July 2017, China implemented combined medication price negotiation and mandatory reimbursement policies for 15 targeted anticancer medications. This study assesses effects of the policy on hospital procurement prices, volume…
Financial Pollution in the US Health Care System
Open AccessAnita K Wagner, Peter A Ubel et al.ARTICLEJAMA Health Forum2021
Wasteful health care spending results from low-value care, undertreatment, pricing failures, fraud, and administrative complexity. 1 Such spending costs US residents between $760 billion and $935 billion each year 1 and harms populations through burdensome health insurance prices and taxes
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China
Open AccessYifan Diao, Jie Qian et al.ARTICLEJournal of Global Health2019
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study Background Evidence is lacking about the impact of emerging government health insurance coverage inclusion on patient utilization and affordability of expensive anti-cancer medicines and insurance sustainability in China
Essential medicines for universal health coverage
Open AccessVeronika J Wirtz, Hans V Hogerzeil et al.ARTICLEThe Lancet2017
Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries
Open AccessCatherine E Vialle-Valentin, Catherine Vialle-Valentin et al.ARTICLEHealth Policy and Planning2015Cited by: 5References: 26
The 2011 United Nations (UN) General Assembly Political Declaration on Prevention and Control of Non-Communicable Diseases (NCDs) brought NCDs to the global health agenda. Essential medicines are central to treating chronic diseases such as hypertension and diabetes. Our study aimed to quantify access to essential medicines for people with chronic conditions in five low- and middle-income countries and to evaluate how household socioeconomic stat…
Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession
Open AccessChristine Leopold, Fang Zhang et al.ARTICLEInternational Journal for Equity…2014
Different policy approaches to contain pharmaceutical expenditures in times of the economic recession in Finland and Portugal had intended--increased use of generics--and likely unintended--slightly decreased overall sales, possibly consistent with decreased access to needed medicines--impacts. These findings highlight the importance of monitoring and evaluating the effects of pharmaceutical policy interventions on use of medicines and health out…
Health care payments in the asia pacific
Open AccessSheila R Reddy, Dennis Ross-Degnan et al.ARTICLEInternational Journal for Equity…2013
Studies that examine economic burden attributable to health care payments should include measures of impoverishment and indebtedness
Household Expenditures for Medicines and the Role of Free Medicines in the Brazilian Public Health System
Andréa Dâmaso Bertoldi, Aluísio J D Barros et al.ARTICLEAmerican Journal of Public Health2011Cited by: 5References: 9
Objectives. We sought to investigate, across different socioeconomic groups, the proportion of household medicine expenses that were paid by households and the proportion paid by the Brazilian national health system. Methods. We carried out a survey in Porto Alegre, Brazil, that included 2988 individuals of all ages. We defined 2 expenditure variables: “out-of-pocket medicines value” (the sum of retail prices of all medicines used by family membe…
Out-of-Pocket Burden of Health Care Spending and the Adequacy of the Medicare Part D Low-Income Subsidy
Becky A Briesacher, Dennis Ross-Degnan et al.ARTICLEMedical Care2010References: 10
BACKGROUND: Evaluating the adequacy of Medicare prescription drug program (Part D) and its low-income subsidy (LIS) requires a comprehensive understanding of drug spending in relation to household resources. OBJECTIVE: : To estimate out-of-pocket health care costs in the year before Part D, in context of total household spending, health status, and LIS eligibility. RESEARCH DESIGN: Nationally representative cross-sectional study. SUBJECTS: Two th…
Segmented regression analysis of interrupted time series studies in medication use research
Open AccessAnita K Wagner, Stephen B Soumerai et al.ARTICLEJournal of Clinical Pharmacy and…2002
Interrupted time series design is the strongest, quasi-experimental approach for evaluating longitudinal effects of interventions. Segmented regression analysis is a powerful statistical method for estimating intervention effects in interrupted time series studies. In this paper, we show how segmented regression analysis can be used to evaluate policy and educational interventions intended to improve the quality of medication use and/or contain c…
A Kiswahili version of the SF-36 Health Survey for use in Tanzania
Open AccessAnita K Wagner, Kaspar Wy et al.ARTICLEQuality of Life Research1999
Validation of the Kiswahili version of the SF-36 Health Survey in a representative sample of an urban population in Tanzania
Open AccessKaspar Wy, K Wyss et al.ARTICLEQuality of Life Research1999
Translating Health Status Questionnaires and Evaluating Their Quality
Open AccessMonika Bullinger, Jordi Alonso et al.ARTICLEJournal of Clinical Epidemiology1998
Patient-based health status measurement in clinical practice
Open AccessAnita K Wagner, Bruce L Ehrenberg et al.ARTICLEQuality of Life Research1997
Advances in methods for assessing the impact of epilepsy and antiepileptic drug therapy on patients' health-related quality of life
Open AccessAnita K Wagner, Sina Keller et al.ARTICLEQuality of Life Research1995
International quality of life assessment (Iqola) project
Open AccessNeil K Aaronson, C Acquadro et al.ARTICLEQuality of Life Research1992

International quality of life assessment (Iqola) project
Open AccessNeil K Aaronson, C Acquadro et al.ARTICLEQuality of Life Research1992
Advances in methods for assessing the impact of epilepsy and antiepileptic drug therapy on patients' health-related quality of life
Open AccessAnita K Wagner, Sina Keller et al.ARTICLEQuality of Life Research1995
Patient-based health status measurement in clinical practice
Open AccessAnita K Wagner, Bruce L Ehrenberg et al.ARTICLEQuality of Life Research1997
Translating Health Status Questionnaires and Evaluating Their Quality
Open AccessMonika Bullinger, Jordi Alonso et al.ARTICLEJournal of Clinical Epidemiology1998
A Kiswahili version of the SF-36 Health Survey for use in Tanzania
Open AccessAnita K Wagner, Kaspar Wy et al.ARTICLEQuality of Life Research1999
Validation of the Kiswahili version of the SF-36 Health Survey in a representative sample of an urban population in Tanzania
Open AccessKaspar Wy, K Wyss et al.ARTICLEQuality of Life Research1999
Segmented regression analysis of interrupted time series studies in medication use research
Open AccessAnita K Wagner, Stephen B Soumerai et al.ARTICLEJournal of Clinical Pharmacy and…2002
Interrupted time series design is the strongest, quasi-experimental approach for evaluating longitudinal effects of interventions. Segmented regression analysis is a powerful statistical method for estimating intervention effects in interrupted time series studies. In this paper, we show how segmented regression analysis can be used to evaluate policy and educational interventions intended to improve the quality of medication use and/or contain c…
Out-of-Pocket Burden of Health Care Spending and the Adequacy of the Medicare Part D Low-Income Subsidy
Becky A Briesacher, Dennis Ross-Degnan et al.ARTICLEMedical Care2010References: 10
BACKGROUND: Evaluating the adequacy of Medicare prescription drug program (Part D) and its low-income subsidy (LIS) requires a comprehensive understanding of drug spending in relation to household resources. OBJECTIVE: : To estimate out-of-pocket health care costs in the year before Part D, in context of total household spending, health status, and LIS eligibility. RESEARCH DESIGN: Nationally representative cross-sectional study. SUBJECTS: Two th…
Household Expenditures for Medicines and the Role of Free Medicines in the Brazilian Public Health System
Andréa Dâmaso Bertoldi, Aluísio J D Barros et al.ARTICLEAmerican Journal of Public Health2011Cited by: 5References: 9
Objectives. We sought to investigate, across different socioeconomic groups, the proportion of household medicine expenses that were paid by households and the proportion paid by the Brazilian national health system. Methods. We carried out a survey in Porto Alegre, Brazil, that included 2988 individuals of all ages. We defined 2 expenditure variables: “out-of-pocket medicines value” (the sum of retail prices of all medicines used by family membe…
Health care payments in the asia pacific
Open AccessSheila R Reddy, Dennis Ross-Degnan et al.ARTICLEInternational Journal for Equity…2013
Studies that examine economic burden attributable to health care payments should include measures of impoverishment and indebtedness
Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession
Open AccessChristine Leopold, Fang Zhang et al.ARTICLEInternational Journal for Equity…2014
Different policy approaches to contain pharmaceutical expenditures in times of the economic recession in Finland and Portugal had intended--increased use of generics--and likely unintended--slightly decreased overall sales, possibly consistent with decreased access to needed medicines--impacts. These findings highlight the importance of monitoring and evaluating the effects of pharmaceutical policy interventions on use of medicines and health out…
Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries
Open AccessCatherine E Vialle-Valentin, Catherine Vialle-Valentin et al.ARTICLEHealth Policy and Planning2015Cited by: 5References: 26
The 2011 United Nations (UN) General Assembly Political Declaration on Prevention and Control of Non-Communicable Diseases (NCDs) brought NCDs to the global health agenda. Essential medicines are central to treating chronic diseases such as hypertension and diabetes. Our study aimed to quantify access to essential medicines for people with chronic conditions in five low- and middle-income countries and to evaluate how household socioeconomic stat…
Essential medicines for universal health coverage
Open AccessVeronika J Wirtz, Hans V Hogerzeil et al.ARTICLEThe Lancet2017
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China
Open AccessYifan Diao, Jie Qian et al.ARTICLEJournal of Global Health2019
How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study Background Evidence is lacking about the impact of emerging government health insurance coverage inclusion on patient utilization and affordability of expensive anti-cancer medicines and insurance sustainability in China
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
Open AccessYichen Zhang, Haishaerjiang Wushouer et al.ARTICLEBMJ Global Health2021
INTRODUCTION: New targeted therapies have changed cancer treatment in the past decades. However, high prices of targeted anticancer medications have increased economic burden for both patients and health insurance systems. In July 2017, China implemented combined medication price negotiation and mandatory reimbursement policies for 15 targeted anticancer medications. This study assesses effects of the policy on hospital procurement prices, volume…
Financial Pollution in the US Health Care System
Open AccessAnita K Wagner, Peter A Ubel et al.ARTICLEJAMA Health Forum2021
Wasteful health care spending results from low-value care, undertreatment, pricing failures, fraud, and administrative complexity. 1 Such spending costs US residents between $760 billion and $935 billion each year 1 and harms populations through burdensome health insurance prices and taxes
Ultraexpensive gene therapies, industry interests and the right to health
Open AccessAdriana Mitsue Ivama-Brummell, Anita K Wagner et al.ARTICLEBMJ Global Health2022
Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
Open AccessYue Zhou, Huseyin Naci et al.ARTICLEBMJ Global Health2023
INTRODUCTION: We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months and high scores on European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). METHODS: We identified applications for cancer drug in WHO EMLs from 2015 to 2021. We extracte…
The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China
Open AccessYu Yang, Yichen Zhang et al.ARTICLEJournal of Global Health2023
Background: High prices of targeted anticancer medicines (TAMs) result in financial toxicity for patients and the health insurance system. How national price negotiation and reimbursement policy affect the accessibility of TAMs for cancer patients remains unknown. Methods: In this population-based cohort study, we used national health insurance claims data in 2017 and identified adult patients with cancer diagnoses for which price-negotiated TAMs…
Preventive Drug Lists Reduce Income-Related Disparities in Medication Adherence Over 2 Years
Dennis Ross-Degnan, Stephanie Argetsinger et al.ARTICLEMedical Care2025References: 23
BACKGROUND: Employers add Preventive Drug Lists (PDLs) to commercial insurance plans to reduce out-of-pocket payments for medicines that treat important chronic illnesses. OBJECTIVE: This study examined the impact of PDLs among patients with pre-existing diabetes. RESEARCH DESIGN: Interrupted time series design with difference-in-difference analysis. SUBJECTS: We identified 5575 patients aged 12-64 with diabetes whose employers adopted PDL covera…